Identification of proteins in human prostate tumor material by two-dimensional gel electrophoresis and mass spectrometry

Alaiya, Ayodele; Oppermann, Madalina; Langridge, J.; Roblick, Uwe J.; Egevad, Lars; Brändstedt, S.; Hellström, Magnus; Linder, Stig; Bergman, Tomas; Jörnvall, Hans; Auer, Gert

doi:10.1007/pl00000858

Cited by 73 publications

(49 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fifteen of the 22 identified proteins were previously been reported to differ in expression between BPH and prostate carcinomas (11)(12)(13). We used the expression patterns of these biomarkers for clustering analysis of BPH and prostate adenocarcinoma and almost all samples were correctly classified, as shown in Fig.…”

Section: Validation Of Differentially Expressed For Tumor Classificatmentioning

confidence: 99%

“…However, our 2nd dimension SDS-polyacrylamide gels consist of 12% homogeneous gels as opposed to the linear gradient (10-13%) gels that were used in the others studies (12,23,24) and our previously published data (10,11). Representative 2-DE gels derived from one of the prostate hyperplasia and prostate cancer samples are shown in Fig.…”

Section: Similarities In the Proteome Of Prostate Tumors Of Differentmentioning

confidence: 99%

“…A number of proteins were identified as potential diagnostic or prognostic markers of prostate cancers (10)(11)(12). Among the identified proteins from human prostate cancers is Protein disulfide isomerase, Enoyl CoA-hydrase, Prohibitin, Cytokeratin-18, HSP-60, HSP-71 kDa, glutathione-S-transferase-π, superoxide dismutase, tropomyosin-2 and triose phosphateisomerase (12,13).…”

Section: Introductionmentioning

confidence: 99%

“…The pattern of expression of many of these proteins in prostate cancer is similar to that found in breast and ovarian cancer. This suggests a high degree of similarity in the protein expression profiles of different epithelial tumors (10,11,14). The usefulness of the identified proteins as potential prostate cancer markers are yet to be validated in a large cohort of clinical materials within an ethnic group or across different ethnic populations.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma

Alaiya

2011

Int J Oncol

View full text Add to dashboard Cite

Abstract. Prostate adenocarcinoma often presents at a late stage, due to a lack of early clinical symptoms and lack of accurate objective markers. This study aimed to identify and validate proteomics-based biomarkers useful for prostate cancer diagnosis and to establish a marker-panel for prostate cancer and benign prostate hyperplasia (BPH). Global protein expression patterns in fresh tissue specimens from 8 patients with prostate carcinoma and 16 with BPH were analyzed by two-dimensional gel electrophoresis. Differentially expressed proteins were identified by MALDI-TOF mass spectrometry. We compared our results with those of published studies and defined a set of common biomarkers. We identified 22 differentially expressed proteins between BPH and prostate carcinomas. The up-regulated proteins in cancer compared to BPH included protein disulfide-isomerase, 14-3-3-protein, Enoyl CoA-hydrase, prohibitin and B-tubulin β-2. Keratin-II, desmin, HSP71, ATP-synthase-β-chain and creatine kinase-β-chain were down-regulated. Survey of the literature showed that 15 of our 22 identified proteins have been previously reported to differ in their expression levels between BPH and prostate cancer by other laboratories. The expression patterns of these biomarkers could successfully cluster BPH and adenocarcinomas as well as prostate cancer of low and high Gleason scores. This study validates protein-biomarkers that can be useful for accurate diagnosis and prognostic monitoring of prostate adenocarcinoma. Despite varied prevalence of the disease between different ethnic populations (i.e., high in Sweden, low in Saudi Arabia); the biomarkers indicate that BPH and prostate cancers are biologically 'homogeneous' in their protein expression patterns across wide geographical regions. IntroductionProstate cancer accounts for approximately 25% of all newly diagnosed cancers and is the second leading cause of cancer deaths among the male population in America (1,2). While the prevalence of prostate cancer is relatively low in Saudi Arabia, it is the most commonly diagnosed cancer in men in Sweden (3). Even though the molecular variations in prostate carcinomas across wide geographical regions have not been extensively studied, the disease is relatively more common among AfroAmericans and often present with advanced stage disease compared to what is observed in American white men (4,5).An improvement and widespread availability in the measurement of PSA, such as PSA density, PSA volume and adjusted age-specific PSA ranges has resulted in early disease diagnosis in the Western world (6). However, many malignant cases still elude early detection and patients often present with metastasis at time of diagnosis (7,8) especially in the less developed world. Patients with occult metastases usually do not benefit from radical prostatectomy or radiotherapy and often respond less favorably to hormonal treatment (5,9). Prostate cancer is biologically heterogeneous with unpredictable aggressive behavior and currently the molecular events underlyin...

show abstract

Section: Validation Of Differentially Expressed For Tumor Classificatmentioning

confidence: 99%

Section: Similarities In the Proteome Of Prostate Tumors Of Differentmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma

Alaiya

2011

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…The same group reported in a subsequent study that 23 proteins out of 800 were somewhat different in amount between BPH and prostate cancer specimens. 28 The more recent gel-free proteomics approach has also been used to search for new biomarkers. Using SELDI-TOF MS, Xiao et al 29 gathered data that identifies prostate cancer with better specificity and selectivity than PSA.…”

Section: Proteomic Approaches For Prostate Cancermentioning

confidence: 99%

Proteome analysis of prostate cancer

Kuruma

Egawa

Ohishi

et al. 2004

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

In this paper, we briefly review cancer proteomics in general, with particular attention to our proteome analyses of prostate cancer. Our efforts include development of new tools and novel approaches to discovering proteins potentially useful as cancer diagnostic and/or prognostic biomarkers or as therapeutic targets. To this end, we analyzed prostate cancer proteomes using twodimensional gel electrophoresis employing agarose gels for the initial isoelectric focusing step (agarose 2-DE), with mass spectrometry used for protein identification. Agarose 2-DE offers advantages over the more widely used immobilized pH gradient 2-DE for separating high molecular mass proteins (15-500 kDa), thereby increasing its power to detect changes in the cancer's high-molecular mass proteomes.

show abstract